Ross Moat Kiniksa Pharmaceuticals, Ltd. (KNSA) insider trading activity

Ross Moat is CHIEF COMMERCIAL OFFICER of Kiniksa Pharmaceuticals, Ltd.. Currently has a direct ownership of 27,674 shares of KNSA, which is worth approximately $559,291. The most recent transaction as insider was on Apr 07, 2025, when has been sold 727 shares (Class A Ordinary Share) at a price of $20.28 per share, resulting in proceeds of $14,743. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 27.7K

21.09% 3M change

70.03% 12M change

Total Value Held $559,291

Ross Moat Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Apr 07 2025	SELL Payment of exercise price or tax liability	$14,743 $20.28 p/Share	727 Reduced 2.56%	27,674 Class A Ordinary Share
Apr 07 2025	BUY Exercise of conversion of derivative security	-	2,477 Added 8.02%	28,401 Class A Ordinary Share
Apr 01 2025	SELL Payment of exercise price or tax liability	$21,421 $21.77 p/Share	984 Reduced 3.66%	25,924 Class A Ordinary Share
Apr 01 2025	BUY Exercise of conversion of derivative security	-	3,352 Added 11.08%	26,908 Class A Ordinary Share
Mar 16 2025	SELL Payment of exercise price or tax liability	$6,602 $22.61 p/Share	292 Reduced 1.22%	23,556 Class A Ordinary Share
Mar 16 2025	BUY Exercise of conversion of derivative security	-	994 Added 4.0%	23,848 Class A Ordinary Share
Jan 15 2025	BUY Grant, award, or other acquisition	$17,888 $16.0 p/Share	1,118 Added 4.66%	22,854 Class A Ordinary Share
Sep 03 2024	SELL Open market or private sale	$1,822,944 $26.61 p/Share	68,506 Reduced 75.91%	21,736 Class A Ordinary Share
Sep 03 2024	BUY Exercise of conversion of derivative security	$728,218 $10.63 p/Share	68,506 Added 43.15%	90,242 Class A Ordinary Share
Sep 02 2024	SELL Payment of exercise price or tax liability	$9,225 $26.74 p/Share	345 Reduced 1.56%	21,736 Class A Ordinary Share
Sep 02 2024	BUY Exercise of conversion of derivative security	-	994 Added 4.31%	22,081 Class A Ordinary Share
Sep 01 2024	SELL Payment of exercise price or tax liability	$37,248 $26.74 p/Share	1,393 Reduced 6.2%	21,087 Class A Ordinary Share
Sep 01 2024	BUY Exercise of conversion of derivative security	-	4,089 Added 15.39%	22,480 Class A Ordinary Share
Jul 15 2024	BUY Grant, award, or other acquisition	$3,302 $15.65 p/Share	211 Added 1.13%	18,391 Class A Ordinary Share
Apr 08 2024	SELL Payment of exercise price or tax liability	$24,218 $17.9 p/Share	1,353 Reduced 7.67%	16,276 Class A Common Share
Apr 08 2024	BUY Exercise of conversion of derivative security	-	2,477 Added 12.32%	17,629 Class A Common Share
Apr 01 2024	SELL Payment of exercise price or tax liability	$17,336 $19.7 p/Share	880 Reduced 5.49%	15,152 Class A Common Share
Apr 01 2024	BUY Exercise of conversion of derivative security	-	1,612 Added 9.14%	16,032 Class A Common Share
Sep 02 2023	SELL Payment of exercise price or tax liability	$9,643 $17.76 p/Share	543 Reduced 3.63%	14,420 Class A Common Share
Sep 02 2023	BUY Exercise of conversion of derivative security	-	994 Added 6.23%	14,963 Class A Common Share
Sep 01 2023	SELL Payment of exercise price or tax liability	$24,029 $17.76 p/Share	1,353 Reduced 8.83%	13,969 Class A Common Share
Sep 01 2023	BUY Exercise of conversion of derivative security	-	2,477 Added 13.92%	15,322 Class A Common Share
Jul 15 2023	BUY Grant, award, or other acquisition	$3,606 $12.35 p/Share	292 Added 2.22%	12,845 Class A Common Share
Apr 10 2023	SELL Payment of exercise price or tax liability	$14,490 $10.71 p/Share	1,353 Reduced 9.73%	12,553 Class A Common Share
Apr 10 2023	BUY Exercise of conversion of derivative security	-	2,477 Added 15.12%	13,906 Class A Common Share

Ross Moat

CHIEF COMMERCIAL OFFICER

Hamilton, D0

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells KNSA shares.

Notify only if

Value

Insider Trading

Get notified when an Kiniksa Pharmaceuticals, Ltd. insider buys or sells KNSA shares.

Notify only if

Operation

Value

Type

News

Receive news related to Kiniksa Pharmaceuticals, Ltd.

Track Activities on KNSA

Account